According to a new study, hypertensive patients with a low count of platelet who took a pill of folic acid and enalapril combined on a daily basis observed a 73% reduction in their threat of first stroke in comparison to patients who had only enalapril each day.
This research is the foremost and biggest of its kind to scrutinize the relationship of platelet count and high homocysteine levels mutually—both of which have an important role to play in the cardiovascular disease development—with first stroke.
Senior author of the study, Yong Huo, said, “Our study has demonstrated that baseline low platelet count and augmented homocysteine can mutually amplify the threat of first stroke. If the results are further substantiated by forthcoming trials, we could raise the hope that we can recognize individuals at high threat of developing first stroke by evaluating both homocysteine & platelet, and we could astonishingly lower stroke threat among this patients subgroup with folic acid—a plain, inexpensive, and safe treatment.”
The team established the threat of first stroke decreased to 1.8% from 5.6% among individuals with high homocysteine levels and low platelet count, creating a 73% risk reduction. Nevertheless, the folic acid had no impact among those with low homocysteine levels and high platelet count.
In a supplementary editorial, Director of the Robarts Research Institute’s Stroke Prevention and Atherosclerosis Research Centre, J. David Spence, said, “Individuals with higher homocysteine levels and lower platelet counts are more prone to have been at greater risk as they had a deficiency of vitamin B12. Among folate-replete individuals, the major nutritional determiner of high levels of homocysteine is B12 insufficiency.”
In a previously published description from the China Stroke Primary Prevention Trial, the research team discovered that folic acid treatment can decrease the threat of first stroke on average by 21% in hypertensive adults by reducing the total levels of homocysteine.
Sasha Farrell is a privileged and versatile content writer and editor in the domains of Pharma, Health, and Medical. Before getting into the writing world, Sasha was working as an STM editor for few renowned authors and publications, which gave head-start to rifle through the Pharma, Health, and Medical Innovations.